Christophe Severin
Impact in
- Hepatology top 5%
- Liver physiology and pathology
-
- Lung Cancer Treatments and Mutations
Papers in
-
- Histone Deacetylase Inhibitors Research 3
- Epigenetics and DNA Methylation 2
- PI3K/AKT/mTOR signaling in cancer 2
- Ubiquitin and proteasome pathways 1
-
- Lung Cancer Treatments and Mutations 2
- Ferroptosis and cancer prognosis 1
- Co-authors
- Linda Rangell (1 shared paper)Lukas C. Amler (1 shared paper)Wenjing Zhu (1 shared paper)Ling Fu (1 shared paper)Ralph Schwall (1 shared paper)Thomas Holcomb (1 shared paper)Somasekar Seshagiri (1 shared paper)Kaumudi Bhawe (1 shared paper)
- Journals
- Development (2 papers)Cancer Research (2 papers)Journal of Medicinal Chemistry (1 paper)Bioorganic & Medicinal Chemistry Letters (1 paper)Molecular Cancer Therapeutics (1 paper)
- Partner nations
- United StatesSwitzerland
In The Last Decade
Christophe Severin
7 papers receiving 576 citations
Peers
Comparison fields: 5 of 48
- Hepatology 171
- Pulmonary and Respiratory Medicine 196
- Developmental Neuroscience 24
- Cancer Research 65
- Molecular Biology 310
Countries citing papers authored by Christophe Severin
This map shows the geographic impact of Christophe Severin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Severin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Severin more than expected).
Fields of papers citing papers by Christophe Severin
This network shows the impact of papers produced by Christophe Severin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Severin. The network helps show where Christophe Severin may publish in the future.
Co-authors
The 25 scholars most cited alongside Christophe Severin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2006 | 377 | |
| 2 | 2020 | 96 | |
| 3 | 2001 | 58 | |
| 4 | 2000 | 29 | |
| 5 | 2018 | 12 | |
| 6 | 2013 | 10 | |
| 7 | Combination efficacy with MetMAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for c-Met inhibitors in combination with EGFR inhibitors | 2008 | 9 |
| 8 | 2020 | 0 |
About Christophe Severin
Christophe Severin is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Hepatology, Cellular and Molecular Neuroscience and Cell Biology, having authored 8 papers that have together received 591 indexed citations. Recurring topics across this work include Liver physiology and pathology (3 papers), Histone Deacetylase Inhibitors Research (3 papers), Epigenetics and DNA Methylation (2 papers), Axon Guidance and Neuronal Signaling (2 papers), Lung Cancer Treatments and Mutations (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), Ubiquitin and proteasome pathways (1 paper) and Ferroptosis and cancer prognosis (1 paper). The work is most often cited by research in Hepatology (171 citations), Pulmonary and Respiratory Medicine (196 citations), Developmental Neuroscience (24 citations), Cancer Research (65 citations) and Molecular Biology (310 citations). Christophe Severin has collaborated with scholars based in United States and Switzerland. Frequent co-authors include Linda Rangell, Lukas C. Amler, Wenjing Zhu, Ling Fu, Ralph Schwall, Thomas Holcomb, Somasekar Seshagiri, Kaumudi Bhawe, Robert L. Yauch and Nerissa Mendoza. Their work appears in journals such as Development, Cancer Research, Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.